Paolo Tarantino: Anticipated evolutions in the assessment of MRD to guide cancer treatment
Paolo Tarantino shared a post on X:
”ENASymp24 day 3: Heather Parsons from Dana-Farber’s Breast Oncology Center reviews the current evidence and anticipated evolutions in the assessment of minimal residual disease to guide cancer treatment. Critical to utilize highly sensitive, fit for purpose assays, and to prove their clinical utility.”
Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023